Soleno Therapeutics achieved significant commercial success in Q4 2025, generating $91.7 million in revenue from VYKAT XR and reaching quarterly net income of $43.4 million. The company saw strong adoption with 1,250 total patient start forms since launch and expanded its prescriber base, while maintaining a robust cash position of over $500 million to support future international expansion and pipeline development.

Soleno Therapeutics reported a net loss of $43.8 million for the first quarter of 2025, compared to a net loss of $21.4 million in the same period of 2024. The company did not generate any revenue as commercialization of VYKAT XR had not commenced during this period. Operating expenses increased significantly, primarily due to increased selling, general and administrative costs in preparation for commercial launch.

Soleno Therapeutics reported a net loss of $55.982 million for the fourth quarter of 2024, with total assets of $330.972 million. The company's New Drug Application for DCCR for Prader-Willi syndrome was accepted by the FDA and granted Priority Review, with an updated PDUFA target action date of March 27, 2025. Commercial readiness activities are well underway.

Soleno Therapeutics reported a net loss of $76.6 million for the third quarter ended September 30, 2024. The FDA accepted the NDA for DCCR with a PDUFA target action date of December 27, 2024.

Soleno Therapeutics reported a net loss of $21.9 million for the second quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $294.6 million as of June 30, 2024. Research and development expenses increased to $12.3 million, and general and administrative expenses rose to $10.9 million.

Soleno Therapeutics reported a net loss of $21.4 million for the quarter ended March 31, 2024. The company's research and development efforts are primarily focused on advancing its lead product candidate, DCCR, for the treatment of PWS. As of March 31, 2024, Soleno had $42.8 million of cash and cash equivalents, $106.8 million of short-term investments, and $8.8 million of long-term investments.

Soleno Therapeutics reported a net loss of $11.3 million for the fourth quarter of 2023. The company's research and development expenses were $8.7 million, and general and administrative expenses were $4.1 million. As of December 31, 2023, Soleno had cash and cash equivalents of approximately $169.7 million.

Soleno Therapeutics reported a net loss of $8.5 million for the second quarter of 2023. The company's research and development expenses were $5.1 million, and general and administrative expenses were $3.2 million. As of June 30, 2023, Soleno had cash and cash equivalents of approximately $19.4 million.

Soleno Therapeutics reported a net loss of $8.4 million for the first quarter of 2023. The company's research and development efforts are primarily focused on advancing its lead product candidate, DCCR, for the treatment of PWS.